Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1

Martin-Higueras, Cristina; Borghese, Lodovica; Torres, Armando; Fraga-Bilbao, Fátima; Santana-Estupiñán, Raquel; Stefanidis, Constantinos J.; Tory, Kálmán; Walli, Adam; Gondra, Leire; Kempf, Caroline; Gessner, Michaela; Habbig, Sandra; Eifler, Lisa; Schmitt, Claus P.; Rüdel, Benjamin; Bartram, Malte P.; Beck, Bodo B.; Hoppe, Bernd

doi:10.1016/j.ekir.2023.10.004

Kidney International Reports

2024

DOI: 10.1016/j.ekir.2023.10.004

|View full text |Cite

Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1

Cristina Martin-Higueras,

Lodovica Borghese,

Armando Torres

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria

Hoppe,

Martin-Higueras,

Borghese

et al. 2025

Kidney International Reports

View full text Add to dashboard Cite

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria

Hoppe,

Martin-Higueras,

Borghese

et al. 2025

Kidney International Reports

View full text Add to dashboard Cite

Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status

Zhu,

Cheung,

Zhang

et al. 2024

Kidney Dis

View full text Add to dashboard Cite

Background: Primary hyperoxaluria (PH) is a rare autosomal recessive disorder, mainly due to the increase in endogenous oxalate production, causing a series of clinical features such as kidney stones, nephrocalcinosis, progressive impairment of renal function, and systemic oxalosis. There are three common genetic causes of glycolate metabolism anomalies. Among them, PH type 1 is the most prevalent and severe type, and early end-stage renal failure often occurs. Summary: This review summarizes primary hyperoxaluria through pathophysiology, genotype, clinical manifestation, diagnosis, and treatment options. And explore the characteristics of Chinese PH patients. Key Messages: Diagnosis of this rare disease is based on clinical symptoms, urinary or blood oxalate concentrations, liver biopsy, and genetic testing. Currently, the main treatment is massive hydration, citrate inhibition of crystallization, dialysis, liver and kidney transplantation, and pyridoxine. Recently, RNA interference drugs have also been used. In addition, technologies such as gene editing and autologous liver cell transplantation are also being developed. C.815_816insGA and c.33_34insC mutation in the AGXT gene could be a common variant in Chinese PH1 population. Mutations at the end of exon 6 account for approximately 50% of all Chinese HOGA1 mutations. Currently, the treatment of PH in China still relies mainly on symptomatic and high-throughput dialysis, with poor prognosis (especially for PH1 patients).

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1

Cited by 2 publications

References 39 publications

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria

Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status

Contact Info

Product

Resources

About